Blue Cloud Softech Solutions Ltd

Dematerialisation/rematerialisation status

• Dematerialisation actions completed within 15 days of receipt for period 01/07/2026 to 30/09/2026.
• Dematerialised securities are listed on the relevant stock exchanges.
• Physical certificates were mutilated and cancelled; depository named as registered owner in records.

Product launch

• BluEdge launched as sovereign AI inference software; execution layer of AccessGenie 5.0.

Launch details

• BluEdge launched on 30 September 2026.
• Deployed and operating in live Indian customer environments.

Product features & IP

• Runs across CPU and GPU platforms with on-premise and in-country deployment.
• Patent-pending intellectual property.

Financial impact

• Financial impact not quantifiable at this stage.

Disclosures

• Press release enclosed as Annexure; available on company website.

Blue Cloud Softech Solutions Limited - Trading Window closed from October 01, 2026; will reopen 48 hours after the announcement of the un-audited standalone and consolidated financial results of the Company for the 2nd quarter ended September 30, 2026

Order details

• US$15.5 million fixed-fee SOW from IBM Cloud Inc for AI infra.
• Awarded to Global Impx Inc., Blue Cloud's US subsidiary.
• Five project milestones with payment tied to milestones.
• Work commenced 24 September 2026; stabilisation and support period to follow.

AGM extension details

• ROC Hyderabad extended the AGM deadline for FY2026 to 30 December 2026.
• Extension requested due to due diligence and share-swap transaction for a US healthcare acquisition.
• AGM date/time/venue will be decided by the Board and intimated to exchanges later.
• Application for extension submitted on 2 September 2026 (SRN AC5777505).
• Company year-end remains 31 March 2026; no final AGM date disclosed yet.

IndiaAI CoE Bhubaneswar partnership

• Blue Cloud confirmed as Industry Partner for the IndiaAI Centre of Excellence Bhubaneswar; MeitY approval in-principle.
• Definitive MoU to record Rs 4 crore contribution and leadership role.
• Centre planned around 10,000 sq ft with dedicated infrastructure.
• Focus areas include healthcare, governance, disaster management, education, and Odisha sectors.
• FY26 consolidated revenue Rs 1,002 crore; up 26% YoY.
• FY26 EBITDA Rs 126.13 crore; margin 12.6%.
• FY26 PAT Rs 60.50 crore; up 37% YoY.
• Q1 FY27 consolidated revenue Rs 292.53 crore; up 41.9% YoY.
• Q1 FY27 EBITDA Rs 59.61 crore; margin 20.4%.
• Q1 FY27 PAT Rs 17.95 crore; up 24.7% YoY.
• Blue Cloud listed on NSE Main Board from 18 August 2026.
• Blue Cloud to provide platforms and expertise to Centre incubated startups.
• MoU execution updates will follow regulatory requirements.

Strategic collaboration

• Blue Cloud enters technology association with Mahesh Babu Foundation to deploy BluHealth for community healthcare.
• GMB Life preventive screening app launched on Apple App Store and Google Play on 31 August 2026.
• Next phase includes BluHealth-enabled kiosks staffed by local doctors.
• Association has nil shareholding and is not a related-party transaction.

Financial and regulatory context

• BluHealth is US FDA-registered and endorsed by IMA and CMA.
• FY2025-26 consolidated revenue: Rs. 1,002 crore, up 26% YoY.
• No material financial impact expected in the current financial year.

Operational details

• BluHealth outputs are non-diagnostic wellness indicators; app links to in-person care as needed.
• Future kiosks will connect digital screening to clinical follow-up with local doctors.

Meeting Details

• Date and time: 1st September 2026 at 4:30 PM.
• Location: Registered office of the company.

Key Agenda Items

• Approve the Notice of the 35th AGM along with Board Report, Corporate Governance Report, and MD&A.
• Appoint Mrs. Sarada Putcha as Scrutinizer for remote e-voting process.
• Finalize Cut-off Date and Remote E-voting schedule for the AGM.
• Consider any other business with the Chair's permission.

Other Notes

Acquisition in-principle approval

• Board grants in-principle approval to evaluate/negotiates 100% acquisition of CareTech AI Inc. via share swap.
• Subject to due diligence, independent valuation, fairness opinion, definitive agreements, and regulatory approvals.

Advisors and governance

• SEBI-registered valuer, merchant banker, and due diligence advisors appointed.
• Board forms committee to negotiate non-binding term sheet and oversee diligence.

Financials and due diligence status

• CareTech revenue: US$80.2m (CY2025); US$67.7m for seven months to 31 Jul 2026.
• Full-year 2026 revenue estimated at US$116m; subject to independent verification.
• No binding LOI or agreements yet; consideration and share count to be determined.
• Promoter/director interests: none; reconfirmation before definitive agreements.

Regulatory disclosures and next steps

• Detailed disclosures to be provided upon definitive terms; investor presentation enclosed.
• CPA-reviewed financial statements from CareTech to be furnished after due diligence.

MSA execution and financials

• Commencement of delivery under the USD 150 million SpaceX MSA begins 24 August 2026.
• Scope under SOW No. 1 covers AI infrastructure, cybersecurity, telecommunications, and data centre solutions.
• US operations will deliver via Blue Cloud USA, expanding international delivery capabilities.
• FY26 revenue ₹1,002 crore; EBITDA ₹126.13 crore; PAT ₹60.50 crore.
• Figures to be reconciled with formally disclosed FY26 results.